<DOC>
	<DOCNO>NCT01808560</DOCNO>
	<brief_summary>The purpose pilot feasibility study ass whether treat meibomian gland dysfunction ( MGD ) prior cataract surgery help promote meibomian gland function , visual quality ocular comfort cataract surgery .</brief_summary>
	<brief_title>Treatment Meibomian Gland Dysfunction Prior Cataract Surgery</brief_title>
	<detailed_description>This post-market , prospective , non-significant risk , open-label , randomized multi-center clinical trial evaluate treatment LipiFlow System patient meibomian gland dysfunction prior plan bilateral cataract surgery . All subject undergo examination determine study eligibility capture Baseline status prior surgery . Subjects randomize receive LipiFlow treatment ( Pre-treatment group ) one month cataract surgery LipiFlow treatment ( Untreated Control group ) . Cataract surgery perform eye subject second eye surgery complete within two month first eye . All subject evaluate one month three month cataract surgery second eye comparison study endpoints Pre-treatment Untreated group . To facilitate subject recruitment , Untreated Control group receive crossover LipiFlow treatment MGD ( Post-treatment group ) three month cataract surgery second eye .</detailed_description>
	<mesh_term>Cataract</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Blepharitis</mesh_term>
	<criteria>55 85 year age Must able comply protocol include study randomization ; completion plan bilateral cataract surgery ; use MGD dry eye treatment study ; attendance study visit Meibomian gland dysfunction eye base total meibomian gland score None mild dry eye symptom base Ocular Surface Disease Index score Tear film interferometry assessment 100 unit less Systemic disease condition cause dry eye Use systemic medication know cause dry eye Use MGD dry eye treatment except counter lubricant dietary supplement History follow ocular condition past 3 month : surgery , trauma , Herpes infection , recurrent inflammation , punctal plug insertion punctal occlusion Presence follow active condition : ocular infection , ocular inflammation , moderate severe allergic conjunctivitis , severe eyelid inflammation , eyelid abnormality affect lid function , ocular surface abnormality compromise corneal integrity Participation another ophthalmic drug device trial past month</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>